Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.
The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.
Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.
Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.
Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.
Vaccinex, a clinical-stage biotechnology firm, announced positive interim results from the Phase Ib segment of the KEYNOTE-B84 study, featuring its drug pepinemab combined with Merck's KEYTRUDA for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Of three patients, two achieved a complete response (CR), despite low PD-L1 biomarker levels. The recommended dose of pepinemab was well tolerated, allowing the continuation of treatment.
Vaccinex plans to expand the trial, enrolling up to an additional 62 patients, and aims to share further findings at a medical conference in 2022.
Vaccinex, Inc. (Nasdaq: VCNX) announced positive interim safety data from the Phase 1b segment of the KEYNOTE B84 study, evaluating the combination of pepinemab and Keytruda in advanced head and neck cancer patients. The safety run-in phase confirmed that pepinemab (20 mg/kg) and Keytruda (200 mg Q3W) were well tolerated, paving the way for the Phase 2 expansion segment, which will enroll up to 62 subjects. This study aims to assess the Objective Response Rate (ORR) and other key metrics, with interim results expected in the second half of 2022.
Vaccinex, Inc. (Nasdaq: VCNX) has announced that Dr. Elizabeth Evans will present a Phase 1/2 study on pepinemab in combination with pembrolizumab for advanced head and neck cancer at the SITC Annual Meeting from November 12-14, 2021. The presentation, Poster #434, will highlight the potential of pepinemab in enhancing treatment efficacy. The poster will be showcased in-person and virtually, with virtual access available until January 9, 2022. Vaccinex aims to leverage its unique drug discovery platform to expand its therapeutic pipeline, particularly in cancer and neurodegenerative diseases.
Vaccinex, Inc. (Nasdaq: VCNX) announces a live presentation by Terrence Fisher, Ph.D., at the Clinical Trials on Alzheimer's Disease Meeting in Boston on November 11, 2021. The presentation will focus on the potential of pepinemab, a SEMA4D-blocking antibody, as a novel treatment for neurodegenerative diseases, supported by clinical proof of concept in Huntington's Disease. Vaccinex aims to leverage its proprietary ActivMAb® platform for future drug development. Further details about the presentation can be found on the company’s website.
Vaccinex, Inc. (Nasdaq: VCNX) has launched clinical trials for its drug pepinemab, targeting advanced recurrent head and neck cancer and Alzheimer’s disease. The Phase 1b/2 trial in head and neck cancer will assess the combination with KEYTRUDA® and aims to enroll 65 subjects, with results expected in H2 2022. The Alzheimer’s study has begun enrollment for 40 subjects, with topline data anticipated in late 2022 or early 2023. Financially, R&D expenses decreased significantly to $3.6 million from $7.3 million year-over-year, while cash reserves increased to $13.8 million.
Vaccinex (Nasdaq: VCNX) announced a virtual presentation by CEO Dr. Maurice Zauderer at the 12th Annual Jefferies London Healthcare Conference on November 18-19, 2021. Investors are invited for one-on-one meetings during this period. The presentation will be accessible from 8:00 am GMT on November 18 until 5:00 pm GMT on November 19. Additionally, the presentation and a replay will be available on Vaccinex's website post-event. The company is focused on treating cancer and neurodegenerative diseases through SEMA4D inhibition, with its lead candidate, pepinemab, currently in clinical evaluation.
Vaccinex, Inc. (Nasdaq: VCNX) announced on November 1, 2021, that Dr. Maurice Zauderer will present at the Virtual Huntington Study Group Meeting on November 5. His presentation will discuss a positive post-hoc subgroup analysis from the SIGNAL Phase 2 trial of pepinemab, indicating cognitive benefits for patients with mildly advanced Huntington's Disease (HD). Dr. Elizabeth E. Evans will also present a related poster. Vaccinex is focused on advancing pepinemab, targeting both neurodegenerative diseases and cancer.
Vaccinex, a clinical-stage biotech firm, announced that COO Elizabeth Evans will present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021. The company is actively enrolling participants for its SIGNAL-AD trial on pepinemab for Alzheimer’s Disease and for the KEYNOTE B84 trial, combining pepinemab with Merck’s KEYTRUDA for head and neck cancer patients. The presentation will provide key insights into Vaccinex's innovative approach to targeting neurodegenerative diseases and cancer through SEMA4D inhibition.
Vaccinex announced promising findings from the SIGNAL Phase 2 Huntington’s Disease Trial presented by CEO Maurice Zauderer at the EHDN2021 meeting. The trial highlighted the cognitive benefits of the pepinemab antibody, especially in patients with moderately advanced HD. A pivotal Phase 3 trial is being planned, with ongoing discussions for potential development partners. The SIGNAL trial included 268 subjects and points towards treating cognitive impairments in HD, a currently incurable disease. The company aims to advance treatments for both HD and Alzheimer's disease.
Vaccinex, Inc. (Nasdaq: VCNX) reported Q2 2021 financial results, ending the period with $22.4 million in cash. The company has commenced two clinical studies: pepinemab as a monotherapy for Alzheimer’s disease and in combination with KEYTRUDA® for metastatic head and neck cancer. Positive interim data from the Huntington’s disease program highlights cognitive improvements and treatment efficacy. Upcoming milestones include topline data from Alzheimer’s trials expected in late 2022/early 2023 and early data from head and neck cancer studies anticipated in late 2022.
FAQ
What is the current stock price of Vaccinex (VCNX)?
What is the market cap of Vaccinex (VCNX)?
What is Vaccinex, Inc.?
Where is Vaccinex, Inc. located?
What is Vaccinex's lead drug candidate?
What is the focus of Vaccinex's research?
What clinical studies is pepinemab involved in?
What is the ActivMAb platform?
Who are Vaccinex's research partners?
What recent milestone has Vaccinex achieved?
How is Vaccinex funded?
Who leads the development team at Vaccinex?
